Conditions

GLP-1 and Heart Disease: Cardiovascular Benefits Explained

GLP-1 Companion · 10 min read

The cardiovascular benefits of GLP-1 receptor agonists represent one of the most important pharmacological advances in cardiometabolic medicine in decades. What began as diabetes medications have proven themselves as cardiovascular protective agents, with effects that go well beyond what can be explained by weight loss or glucose lowering alone. Understanding the evidence — and who benefits most — is essential for patients with heart disease and their providers.

The Landmark Cardiovascular Outcomes Trials

LEADER Trial: Liraglutide

The LEADER trial enrolled 9,340 patients with type 2 diabetes at high cardiovascular risk, comparing liraglutide versus placebo on a background of standard care. Over a median follow-up of 3.8 years, liraglutide reduced the primary composite endpoint of major adverse cardiovascular events (MACE: non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death) by 13% (HR 0.87, 95% CI 0.78-0.97, p=0.01). Cardiovascular death specifically was reduced by 22%, and all-cause mortality was reduced by 15%. Published in the New England Journal of Medicine in 2016, LEADER was the first GLP-1 trial to demonstrate clear cardiovascular superiority.

SUSTAIN-6: Semaglutide

The SUSTAIN-6 trial evaluated once-weekly semaglutide in 3,297 patients with type 2 diabetes and high cardiovascular risk over 104 weeks. Semaglutide reduced MACE by 26% compared to placebo (HR 0.74, 95% CI 0.58-0.95, p<0.001 for noninferiority, p=0.02 for superiority). Non-fatal stroke was particularly reduced (HR 0.61), though the mechanism for this remains an active area of research. While SUSTAIN-6 was a noninferiority trial with a relatively small sample size, it set the stage for larger confirmatory trials.

REWIND: Dulaglutide

The REWIND trial was notable for including a broader population: 46% of participants had no prior cardiovascular disease but had multiple cardiovascular risk factors. Over a median follow-up of 5.4 years, dulaglutide reduced MACE by 12% (HR 0.88, 95% CI 0.79-0.99). Importantly, the benefit was consistent regardless of prior cardiovascular disease status, suggesting GLP-1 cardiovascular protection extends to primary prevention in high-risk individuals.

SELECT Trial: Semaglutide Without Diabetes

The SELECT trial, published in 2023, was a landmark study that enrolled 17,604 adults with pre-existing cardiovascular disease and obesity (BMI ≥27) but without diabetes. Participants received semaglutide 2.4 mg weekly or placebo in addition to standard care. After a mean follow-up of 33.6 months, semaglutide reduced MACE by 20% (HR 0.80, 95% CI 0.72-0.90, p<0.001). This was the first cardiovascular outcomes trial to demonstrate GLP-1 benefit in a non-diabetic population, strongly suggesting that the cardiovascular protection is not entirely mediated by glucose lowering.

Mechanisms of Cardiovascular Protection

Beyond Weight Loss and Glucose Lowering

The magnitude of cardiovascular benefit in trials like SELECT exceeds what would be predicted by weight loss alone. Analyses accounting for achieved weight loss and HbA1c reduction still show residual cardiovascular benefit, pointing to direct cardioprotective mechanisms.

• Anti-inflammatory effects: GLP-1 receptor agonists reduce circulating inflammatory markers including CRP, IL-6, and TNF-alpha, reducing the chronic vascular inflammation that drives atherosclerosis progression.
• Direct cardiac effects: GLP-1 receptors are expressed in myocardial tissue. Activation improves cardiac contractility, reduces ischemia-reperfusion injury in animal models, and may support cardiomyocyte survival.
• Blood pressure reduction: Semaglutide and liraglutide consistently reduce systolic blood pressure by 2-5 mmHg through natriuretic and vasodilatory effects.
• Endothelial function improvement: GLP-1 agents improve endothelial nitric oxide production, reducing arterial stiffness and improving flow-mediated dilation.
• Lipid modification: Modest reductions in LDL cholesterol, triglycerides, and remnant particles have been observed, reducing atherogenic lipid burden.
• Plaque stabilization: Animal and human studies suggest GLP-1 receptor activation may stabilize atherosclerotic plaques, reducing vulnerability to rupture.

Heart Failure Benefits

The STEP-HFpEF trial (2023) specifically evaluated semaglutide 2.4 mg in patients with heart failure with preserved ejection fraction (HFpEF) and obesity. Over 52 weeks, semaglutide reduced the Kansas City Cardiomyopathy Questionnaire (KCCQ) score — a key measure of symptoms and quality of life — by 7.8 points more than placebo, and reduced 6-minute walk distance decline. This established GLP-1 utility specifically in the fast-growing HFpEF population, where no other therapy had previously shown similar symptom benefit.

Who Benefits Most From GLP-1 Cardiovascular Protection

• Patients with established atherosclerotic cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) — the most robust evidence base.
• Patients with heart failure with preserved ejection fraction (HFpEF) and obesity.
• High-risk primary prevention patients with obesity plus multiple cardiovascular risk factors (hypertension, dyslipidemia, smoking, family history).
• Patients with type 2 diabetes and cardiovascular disease, where GLP-1 agents are now first-line add-on therapy in major guidelines.
• Patients who cannot achieve adequate risk-factor control through lifestyle modification alone.

Which GLP-1 Has the Strongest Cardiovascular Evidence?

Among the approved GLP-1 receptor agonists, semaglutide has the broadest cardiovascular evidence, including SELECT (non-diabetic population), SUSTAIN-6 (diabetic population), and STEP-HFpEF (heart failure). Liraglutide has strong evidence from LEADER. Dulaglutide's REWIND data extend benefit to primary prevention. Notably, tirzepatide's dedicated cardiovascular outcomes trial (SURMOUNT-MMO) results were eagerly anticipated as of 2026 but not yet fully published.

Practical Guidance for Patients With Heart Disease

• If you have established cardiovascular disease and are overweight or have type 2 diabetes, discuss with your cardiologist whether a GLP-1 medication is appropriate.
• GLP-1 medications are now listed as first-line add-on therapy in both the ADA and ACC/AHA guidelines for patients with T2D and cardiovascular disease.
• The cardiovascular benefit is a class effect (supported for semaglutide, liraglutide, dulaglutide), not limited to one agent.
• Heart rate increases of 2-4 bpm are common with GLP-1 medications — monitor in patients with baseline tachycardia or atrial fibrillation.
• GLP-1 medications have not shown benefit in acute heart failure and should not be initiated during decompensated heart failure hospitalization.

The SELECT trial result was a paradigm shift. GLP-1 medications are no longer just diabetes drugs that happen to protect the heart — they are cardiovascular drugs that also manage weight and blood sugar. The conversation with patients who have heart disease needs to reflect that reality.

The Bottom Line

The cardiovascular outcomes data for GLP-1 receptor agonists are among the most robust in modern medicine. LEADER (13% MACE reduction), SUSTAIN-6 (26%), REWIND (12%), and SELECT (20% in non-diabetic patients) collectively establish GLP-1 agents — particularly semaglutide and liraglutide — as cardiovascular protective medications. The mechanisms go beyond weight and glucose lowering to include anti-inflammatory, endothelial, and direct cardiac effects. Patients with existing heart disease and those at high risk should have this conversation with their care team.

Sources

• Lincoff et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity. NEJM.
• Kosiborod et al. (2023). Semaglutide in Patients with Heart Failure. NEJM.